JP2021512120A5 - - Google Patents

Info

Publication number
JP2021512120A5
JP2021512120A5 JP2020541922A JP2020541922A JP2021512120A5 JP 2021512120 A5 JP2021512120 A5 JP 2021512120A5 JP 2020541922 A JP2020541922 A JP 2020541922A JP 2020541922 A JP2020541922 A JP 2020541922A JP 2021512120 A5 JP2021512120 A5 JP 2021512120A5
Authority
JP
Japan
Prior art keywords
vsig3
antibody
chain variable
variable region
clones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020541922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512120A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016301 external-priority patent/WO2019152810A1/en
Publication of JP2021512120A publication Critical patent/JP2021512120A/ja
Publication of JP2021512120A5 publication Critical patent/JP2021512120A5/ja
Pending legal-status Critical Current

Links

JP2020541922A 2018-02-02 2019-02-01 Vistaとvsig3との相互作用を調節する化合物ならびにその製造および使用方法 Pending JP2021512120A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862625594P 2018-02-02 2018-02-02
US62/625,594 2018-02-02
US201862627478P 2018-02-07 2018-02-07
US62/627,478 2018-02-07
PCT/US2019/016301 WO2019152810A1 (en) 2018-02-02 2019-02-01 Compounds that modulate the interaction of vista and vsig3 and methods of making and using

Publications (2)

Publication Number Publication Date
JP2021512120A JP2021512120A (ja) 2021-05-13
JP2021512120A5 true JP2021512120A5 (https=) 2022-02-09

Family

ID=65444360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541922A Pending JP2021512120A (ja) 2018-02-02 2019-02-01 Vistaとvsig3との相互作用を調節する化合物ならびにその製造および使用方法

Country Status (5)

Country Link
US (1) US11787857B2 (https=)
EP (1) EP3746477A1 (https=)
JP (1) JP2021512120A (https=)
CN (1) CN111868082A (https=)
WO (1) WO2019152810A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018027042A1 (en) 2016-08-03 2018-02-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
KR20220051164A (ko) 2019-07-05 2022-04-26 아이오엠엑스 테라퓨틱스 아게 Igsf11 (vsig3)의 항체 결합 igc2 및 이의 용도
EP4175668A1 (en) 2020-07-06 2023-05-10 iOmx Therapeutics AG Antibodies binding igv of igsf11 (vsig3) and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5149491A (en) 1990-07-10 1992-09-22 General Electric Company Seed and blanket fuel arrangement for dual-phase nuclear reactors
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6982323B1 (en) 1997-12-23 2006-01-03 Alexion Pharmaceuticals, Inc. Chimeric proteins for diagnosis and treatment of diabetes
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CA2377513A1 (en) 1999-06-25 2001-01-04 Universitat Zurich Hetero-associating coiled-coil peptides
WO2001001137A1 (en) 1999-06-30 2001-01-04 Children's Medical Center Corporation Fusion protein and uses thereof
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US6562576B2 (en) 2001-01-04 2003-05-13 Myriad Genetics, Inc. Yeast two-hybrid system and use thereof
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
EP1513934B1 (en) 2002-06-06 2011-03-02 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
US7807619B2 (en) 2004-11-01 2010-10-05 The Regents Of The University Of California Compositions and methods for modification of biomolecules
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US20180237525A9 (en) 2010-03-26 2018-08-23 Randolph J. Noelle VISTA Agonist and Methods of Use
EP3202419A1 (en) 2012-06-06 2017-08-09 OncoMed Pharmaceuticals, Inc. Pvrig binding agents that modulate the hippo pathway and uses thereof
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
JP6285923B2 (ja) 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規VISTA−Igコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのVISTA−Igの使用
US9381244B2 (en) 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
WO2016020880A2 (en) * 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
CA2969730A1 (en) * 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
WO2018027042A1 (en) 2016-08-03 2018-02-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using

Similar Documents

Publication Publication Date Title
CN109651507B (zh) 一种激动型4-1bb单克隆抗体
JP7600328B2 (ja) PD-1とTGF-betaを標的とした四価二重特異性抗体、その製造方法および用途
JP2023538945A5 (https=)
WO2022166940A1 (en) Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors
JP2023134705A5 (https=)
JP2018502050A5 (https=)
JP2021512120A5 (https=)
JP2022104966A (ja) a-syn/IGF1Rに対する二重特異抗体およびその用途
EP3768721A1 (en) Novel anti-ctla-4 antibody polypeptide
CA3121565A1 (en) Cd3 antibody and pharmaceutical use thereof
CN118984839B (zh) 一种抗ccr8抗体或其抗原结合片段
US20220340677A1 (en) Split intein and preparation method for recombinant polypeptide using the same
CN115605511A (zh) 抗tigit的抗体、其制备方法和应用
CN113166269B (zh) 对抗检查点分子的多特异性结合构建体及其用途
KR20200013233A (ko) 신규 항 cd3 항체
RU2019134462A (ru) Антитела, связывающиеся с steap-1
CN109721656B (zh) 靶向rankl的治疗性抗体
CN114790242A (zh) 一种结合人pd-l1的抗体
JP2022500455A5 (https=)
CN113677701B (zh) 产生亲合结合多特异性抗体的方法
WO2023131328A9 (zh) 一种抗体及其用途
JP2021506310A5 (https=)
CN118251419A (zh) 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
JP7652705B2 (ja) Btn2に対する特異性を有する抗体及びその使用
CN115746144B (zh) 抗tigit-pd1双特异性抗体及其应用